According to Zacks, “X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. “
Several other research firms have also commented on XFOR. ValuEngine lowered shares of X4 Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Cowen reissued a “buy” rating on shares of X4 Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $27.00.
NASDAQ:XFOR traded down $0.01 during mid-day trading on Friday, hitting $11.75. 17,338 shares of the company’s stock were exchanged, compared to its average volume of 60,597. X4 Pharmaceuticals has a one year low of $6.90 and a one year high of $29.46. The company has a debt-to-equity ratio of 0.25, a current ratio of 7.32 and a quick ratio of 7.32. The company has a fifty day moving average price of $13.09.
X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.18). On average, equities research analysts expect that X4 Pharmaceuticals will post -4.77 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Polaris Venture Management Co. V L.L.C. bought a new stake in X4 Pharmaceuticals during the first quarter worth about $5,423,000. Cormorant Asset Management LP raised its holdings in X4 Pharmaceuticals by 252.3% in the second quarter. Cormorant Asset Management LP now owns 890,387 shares of the company’s stock worth $13,356,000 after buying an additional 637,638 shares during the last quarter. Strs Ohio raised its holdings in X4 Pharmaceuticals by 779.6% in the second quarter. Strs Ohio now owns 1,900 shares of the company’s stock worth $28,000 after buying an additional 1,684 shares during the last quarter. Orbimed Advisors LLC raised its holdings in X4 Pharmaceuticals by 200.6% in the second quarter. Orbimed Advisors LLC now owns 936,493 shares of the company’s stock worth $14,047,000 after buying an additional 625,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in X4 Pharmaceuticals in the second quarter worth about $317,000. 61.10% of the stock is currently owned by institutional investors and hedge funds.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Read More: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.